VistaGen Therapeutics's total assets for Q2 2026 were $80.93M, an increase of 17.42% from the previous quarter. VTGN total liabilities were $14.59M for the fiscal quarter, a 19.99% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.